American Society of Hematology (ASH) 2023
Review presentations and information shared by Dana-Farber physician-scientists at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego.
Dana-Farber Showcases Research at 65th American Society of Hematology Annual Meeting and Exposition
Bispecific antibody drives myeloma precursor condition to undetectable levels in phase II trial (Abstract 206, Omar Nadeem, MD)
Antibody drug sharply reduces risk of severe chronic graft-versus-host disease in patients undergoing allogeneic stem cell transplant, trial shows (Abstract 649, Corey Cutler, MD, MPH)
Pilot study uses circulating tumor DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma (DLBCL) (Abstract 527, Reid Merryman, MD)
DETERMINATION trial subgroup analysis suggests potential strategies for individualization of myeloma treatment (Abstract 4762, Paul Richardson, MD)
Adult Stem Cell Transplantation Program
Cellular Therapies Program
Highlights from Previous ASH Meetings
Subscribe to “Advances in Hematologic Malignancies” to receive our bi-annual enewsletter with research and clinical updates, providing comprehensive information about our Division of Hematologic Malignancies.
Follow us on X (formerly Twitter)